Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human ...
A 59-year-old metastatic breast cancer patient experienced rapid symptom improvement with HT-001 therapy, discontinuing treatment after one week. HT-001, developed by Hoth Therapeutics, shows promise for managing EGFRI-associated skin toxicities, enhancing patient quality of life without interrupting cancer therapy.
Reference News
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human ...
A 59-year-old metastatic breast cancer patient experienced rapid symptom improvement with HT-001 therapy, discontinuing treatment after one week. HT-001, developed by Hoth Therapeutics, shows promise for managing EGFRI-associated skin toxicities, enhancing patient quality of life without interrupting cancer therapy.